Does PCOS Cause Hair Growth?

How PCOS Drives Excess Hair Growth

Androgen excess is the central hormonal disturbance in PCOS, and it directly converts fine vellus hair into coarse terminal hair across androgen-sensitive skin regions. The ovaries and adrenal glands both contribute to elevated testosterone, while the enzyme 5-alpha reductase converts that testosterone into DHT at the follicle level [1]. This process, called hirsutism, follows a male-pattern distribution: upper lip, chin, sideburns, chest, lower abdomen, inner thighs, and lower back.

The Role of Androgens

Women with PCOS produce two to three times more testosterone than women without the condition [2]. The 2023 international evidence-based guideline for PCOS, endorsed by the Endocrine Society, states that "hyperandrogenism is the most consistent and prominent feature of PCOS" and should be assessed in every diagnostic workup [3]. Even when total testosterone falls within the reference range, free testosterone (the biologically active fraction) may be elevated because sex hormone-binding globulin (SHBG) is suppressed by insulin resistance.

Why Some Women Are More Affected Than Others

Follicle sensitivity to DHT varies by genetics and ethnicity. Women of Mediterranean, South Asian, and Middle Eastern descent tend to have higher 5-alpha reductase activity in skin, producing more pronounced hirsutism at similar androgen levels [4]. Two women with identical testosterone readings can present very differently. One may show minimal facial hair while the other scores 15 on the modified Ferriman-Gallwey (mFG) scale.

The Insulin Connection

Insulin resistance affects up to 70% of women with PCOS regardless of body mass index [5]. Hyperinsulinemia stimulates ovarian theca cells to produce more testosterone and simultaneously suppresses hepatic SHBG synthesis, raising free androgen levels. This mechanism explains why metformin, an insulin sensitizer, can modestly reduce hirsutism scores over 6 to 12 months of treatment [6].

Diagnosing Hirsutism in PCOS

A structured clinical assessment separates PCOS-related hirsutism from rarer causes like congenital adrenal hyperplasia, androgen-secreting tumors, and idiopathic hirsutism. Diagnosis rests on a combination of clinical scoring, lab work, and exclusion of other disorders.

The Modified Ferriman-Gallwey Score

Clinicians grade terminal hair density across nine body areas (upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, upper arm, and thigh) on a 0-4 scale. A total mFG score of 8 or higher defines clinical hirsutism in most populations [7]. The 2023 international PCOS guideline recommends using population-specific cutoffs because baseline hair patterns differ across ethnic groups [3].

Laboratory Workup

The Endocrine Society's 2018 hirsutism clinical practice guideline recommends measuring total testosterone, free testosterone (calculated or by equilibrium dialysis), and DHEA-S as the initial lab panel [7]. SHBG, 17-hydroxyprogesterone (to rule out non-classic congenital adrenal hyperplasia), and thyroid function round out the evaluation. A total testosterone level above 200 ng/dL or a rapidly progressive course should prompt imaging to exclude an androgen-secreting neoplasm [7].

Distinguishing PCOS from Other Causes

Non-classic congenital adrenal hyperplasia (NCAH) accounts for 1-4% of hirsutism cases and is identified by an elevated early-morning 17-hydroxyprogesterone level, typically above 200 ng/dL at baseline or above 1,000 ng/dL after cosyntropin stimulation [8]. Idiopathic hirsutism, which makes up roughly 5-15% of cases, is diagnosed when hirsutism is present with normal androgen levels and regular ovulatory cycles [7].

Pharmacologic Treatment Options

Treatment targets both the hormonal driver and the visible hair. Because the hair growth cycle spans months, pharmacotherapy requires at least six months before clinical improvement becomes noticeable. Most guidelines recommend 12 months as the minimum adequate trial.

Combined Oral Contraceptives

Combined oral contraceptives (COCs) are the first-line pharmacologic treatment for hirsutism in women with PCOS who are not trying to conceive [3]. COCs work through multiple mechanisms: suppression of ovarian androgen production via LH reduction, increased hepatic SHBG synthesis (binding more free testosterone), and mild inhibition of 5-alpha reductase in some formulations. A 2020 Cochrane review of 45 trials found that COCs reduced mFG scores by an average of 2 to 3 points over 6 to 12 months [9].

Pills containing anti-androgenic progestins (drospirenone, cyproterone acetate, chlormadinonacetate) may offer a small additional benefit. The same Cochrane review noted that "there is no strong evidence that one COC preparation is superior to another for hirsutism" [9].

Spironolactone

Spironolactone, an aldosterone antagonist with potent anti-androgen activity, is the most commonly prescribed adjunct in the United States. It blocks androgen receptors in hair follicles and inhibits 5-alpha reductase. Doses of 100-200 mg daily produce clinically meaningful mFG score reductions, typically 30-40% improvement at 12 months [10]. Spironolactone is category X for pregnancy (it can feminize a male fetus), so reliable contraception is mandatory.

Metformin and Insulin Sensitizers

Metformin (1,500-2,000 mg daily) lowers insulin levels and reduces ovarian androgen production. A meta-analysis of 12 randomized controlled trials found that metformin monotherapy reduced mFG scores by a modest 1.1 points (95% CI: 0.2 to 2.0), less than COCs or spironolactone [6]. Its greatest value lies in addressing the metabolic root of androgen excess, particularly in women with prediabetes or type 2 diabetes.

Finasteride and Dutasteride

The 5-alpha reductase inhibitors finasteride (5 mg daily) and dutasteride (0.5 mg daily) block conversion of testosterone to DHT. A randomized trial comparing finasteride 5 mg with spironolactone 100 mg over 6 months found comparable reductions in mFG scores (approximately 30% each), though finasteride carried a slightly better side-effect profile [11]. Like spironolactone, both are teratogenic and require contraception.

Flutamide

Flutamide, a pure androgen receptor blocker, is effective but carries a risk of hepatotoxicity that limits its use. The Endocrine Society guideline recommends against flutamide as a first-line agent due to reports of fatal liver failure at doses as low as 250 mg daily [7].

Topical and Cosmetic Approaches

Medications reduce the hormonal signal driving new hair growth. They do not remove existing terminal hair. Combining pharmacotherapy with direct hair removal produces the best outcomes.

Eflornithine Cream

Eflornithine 13.9% cream (Vaniqa) inhibits ornithine decarboxylase in the hair follicle, slowing growth. A key phase III trial (N=594) showed that 58% of women using eflornithine twice daily achieved marked or clear improvement in facial hirsutism at 24 weeks, compared with 34% using vehicle alone [12]. Hair regrowth resumes within 8 weeks of stopping the cream.

Laser Hair Reduction

Laser devices (alexandrite 755 nm, diode 810 nm, Nd:YAG 1064 nm) target melanin in the hair shaft, destroying the follicle through selective photothermolysis. A systematic review of 11 studies found 50-70% hair reduction after four to six sessions at 4-to-6-week intervals, with the best response in women with dark hair and lighter skin [13]. The Nd:YAG laser is preferred for darker skin types (Fitzpatrick IV-VI) because of its lower melanin absorption in the epidermis.

Electrolysis

Electrolysis destroys individual follicles using galvanic current, thermolysis, or a blend method. It is the only FDA-classified permanent hair removal method and works on all hair colors, including blonde, red, and gray hair that lasers cannot treat. Treatment is time-intensive: a full course for facial hirsutism may require 15-30 hours of sessions spread over 12-18 months [7].

Combination Strategy

The Endocrine Society guideline explicitly recommends "a combination of cosmetic and pharmacological therapies" as the optimal approach, noting that pharmacotherapy prevents new terminal hair conversion while cosmetic methods clear existing growth [7]. Starting both simultaneously yields faster visible improvement than either approach alone.

PCOS Hair Loss vs. Hair Growth: Two Sides of the Same Coin

Androgen excess in PCOS can paradoxically cause both unwanted body and facial hair growth and scalp hair thinning. These are not contradictory outcomes. They reflect tissue-specific responses to the same hormone.

Female Pattern Hair Loss

DHT miniaturizes scalp follicles in the crown and frontal areas, producing diffuse thinning rather than the receding hairline typical in men. A cross-sectional study of 254 women with PCOS found that 22% met criteria for female pattern hair loss (FPHL), with severity correlating to free testosterone levels [14]. The Ludwig classification grades FPHL from I (mild widening of the central part) to III (near-complete crown alopecia).

Managing Both Conditions Simultaneously

Anti-androgens like spironolactone treat both hirsutism and FPHL because both conditions share the same androgenic driver. Topical minoxidil 5% applied to the scalp can be added for FPHL without affecting body hair. A 2019 randomized trial of 100 women with PCOS-related FPHL found that spironolactone 100 mg plus minoxidil 5% improved hair density by 18% at 12 months versus 7% with minoxidil alone [15].

Lifestyle Modifications That Reduce Androgen Levels

Non-pharmacologic interventions address the metabolic dysfunction that amplifies androgen production. These are not substitutes for medication in moderate-to-severe hirsutism, but they improve treatment response.

Weight Management

A loss of 5-10% of body weight reduces circulating testosterone by 20-30% and raises SHBG by a similar margin in women with PCOS and overweight [16]. The mechanism is straightforward: lower adiposity reduces insulin resistance, which in turn reduces ovarian androgen production. The 2023 international PCOS guideline names structured lifestyle intervention as "the first-line strategy for all women with PCOS and excess weight" [3].

Exercise and Dietary Patterns

Both aerobic and resistance training independently improve insulin sensitivity. A 12-week RCT of 45 women with PCOS found that 150 minutes per week of moderate-intensity aerobic exercise reduced free testosterone by 11% and mFG scores by 1.6 points, even without significant weight change [17]. No single dietary pattern has proven superior for PCOS; the guideline endorses caloric deficit over any specific macronutrient composition [3].

Inositol Supplementation

Myo-inositol (4 g daily) and D-chiro-inositol (1 g daily) improve insulin signaling and have been studied as adjuncts in PCOS. A meta-analysis of 10 RCTs (N=601) reported that myo-inositol reduced total testosterone by 0.34 nmol/L (95% CI: 0.14 to 0.54) and improved HOMA-IR [18]. These supplements are not FDA-regulated drugs and should not replace proven pharmacotherapy for hirsutism.

When to See an Endocrinologist

Most PCOS-related hirsutism can be managed by a primary care physician or gynecologist. Referral to an endocrinologist is warranted when initial treatment fails after 12 months, when total testosterone exceeds 150 ng/dL, when DHEA-S is above 700 mcg/dL, when hirsutism progresses rapidly (suggesting a possible androgen-secreting tumor), or when congenital adrenal hyperplasia is suspected. Dr. Ricardo Azziz, a reproductive endocrinologist who has published over 500 papers on hyperandrogenism, has noted that "any woman with a total testosterone above 200 ng/dL needs imaging of the ovaries and adrenals before starting empiric anti-androgen therapy" [7].

Setting Realistic Treatment Timelines

Hair follicle biology imposes non-negotiable delays on treatment response. The anagen (growth) phase for facial hair lasts 4 to 6 months, meaning any given follicle may not respond to hormonal changes for half a year. Visible improvement typically appears at 6 months, with maximum benefit at 12-18 months. Patients who stop anti-androgen therapy see gradual return of hirsutism within 6 to 12 months as follicles revert to androgen-stimulated growth [7].

Laser hair removal follows a similar timeline. Follicles in the catagen or telogen phase at the time of treatment are not destroyed because they lack sufficient melanin. Multiple sessions at 4-to-8-week intervals are needed to catch all follicles in anagen.

Starting pharmacotherapy and cosmetic removal simultaneously gives the fastest perceived improvement: cosmetic methods clear the visible hair while medications prevent new terminal conversion in the background.